CN103167800A - 即用型酮咯酸注射液 - Google Patents

即用型酮咯酸注射液 Download PDF

Info

Publication number
CN103167800A
CN103167800A CN201180050372XA CN201180050372A CN103167800A CN 103167800 A CN103167800 A CN 103167800A CN 201180050372X A CN201180050372X A CN 201180050372XA CN 201180050372 A CN201180050372 A CN 201180050372A CN 103167800 A CN103167800 A CN 103167800A
Authority
CN
China
Prior art keywords
pharmaceutical composition
ketorolac
composition
acceptable salt
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180050372XA
Other languages
English (en)
Chinese (zh)
Inventor
约瑟夫·培高利兹
亚历山大·米罗诺夫
查德·詹姆斯·皮肯斯
道格拉斯·贾尔斯·约翰逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RTU PHARMACEUTICALS LLC
Original Assignee
RTU PHARMACEUTICALS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RTU PHARMACEUTICALS LLC filed Critical RTU PHARMACEUTICALS LLC
Priority to CN201810988217.6A priority Critical patent/CN108703948A/zh
Publication of CN103167800A publication Critical patent/CN103167800A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201180050372XA 2010-10-21 2011-10-21 即用型酮咯酸注射液 Pending CN103167800A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810988217.6A CN108703948A (zh) 2010-10-21 2011-10-21 即用型酮咯酸注射液

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40538410P 2010-10-21 2010-10-21
US61/405,384 2010-10-21
US201161481602P 2011-05-02 2011-05-02
US61/481,602 2011-05-02
PCT/US2011/057284 WO2012054831A2 (en) 2010-10-21 2011-10-21 Ready to use ketorolac formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810988217.6A Division CN108703948A (zh) 2010-10-21 2011-10-21 即用型酮咯酸注射液

Publications (1)

Publication Number Publication Date
CN103167800A true CN103167800A (zh) 2013-06-19

Family

ID=45973506

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810988217.6A Pending CN108703948A (zh) 2010-10-21 2011-10-21 即用型酮咯酸注射液
CN201180050372XA Pending CN103167800A (zh) 2010-10-21 2011-10-21 即用型酮咯酸注射液

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810988217.6A Pending CN108703948A (zh) 2010-10-21 2011-10-21 即用型酮咯酸注射液

Country Status (19)

Country Link
US (5) US9421191B2 (enExample)
EP (3) EP3632432B1 (enExample)
JP (1) JP6013346B2 (enExample)
KR (4) KR102307601B1 (enExample)
CN (2) CN108703948A (enExample)
CA (1) CA2814805C (enExample)
CY (1) CY1122516T1 (enExample)
DK (1) DK2616064T3 (enExample)
ES (2) ES2933198T3 (enExample)
HR (1) HRP20191994T1 (enExample)
HU (1) HUE045889T2 (enExample)
LT (1) LT2616064T (enExample)
MX (1) MX346879B (enExample)
PL (1) PL2616064T3 (enExample)
PT (1) PT2616064T (enExample)
RS (1) RS59526B1 (enExample)
SI (1) SI2616064T1 (enExample)
SM (1) SMT201900656T1 (enExample)
WO (1) WO2012054831A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103830171A (zh) * 2014-03-04 2014-06-04 鲁南制药集团股份有限公司 一种酮咯酸氨丁三醇注射液及其制备方法
CN110812325A (zh) * 2019-11-13 2020-02-21 鲁南制药集团股份有限公司 一种提高酮咯酸氨丁三醇注射液存储稳定性的方法
CN113384524A (zh) * 2021-07-05 2021-09-14 四川尚锐生物医药有限公司 一种稳定的酮咯酸氨丁三醇注射液的制备方法
CN114191384A (zh) * 2021-12-20 2022-03-18 成都倍特药业股份有限公司 一种即用型酮咯酸氨丁三醇和氢溴酸依他佐辛组合液体制剂
WO2022241983A1 (zh) * 2020-05-19 2022-11-24 南京海融医药科技股份有限公司 一种左酮咯酸的药物组合物及其制备方法
CN115518035A (zh) * 2021-06-24 2022-12-27 上海博志研新药物技术有限公司 一种酮咯酸液体组合物、其制备方法及应用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012054831A2 (en) 2010-10-21 2012-04-26 Rtu Pharmaceuticals, Llc Ready to use ketorolac formulations
US10098872B1 (en) 2013-07-22 2018-10-16 William Bradley Worthington Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11559521B2 (en) * 2013-07-22 2023-01-24 William Bradley Worthington Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11992484B2 (en) 2013-07-22 2024-05-28 Hutchison Health, Llc Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11992485B2 (en) 2013-07-22 2024-05-28 Hutchison Health, Llc Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP4008319B1 (en) * 2015-11-25 2024-11-20 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
IT201600075246A1 (it) * 2016-07-19 2018-01-19 Jointherapeutics S R L Composizioni comprendenti una matrice polisaccaridica per il rilascio controllato di principi attivi.
KR102583443B1 (ko) * 2017-05-10 2023-09-26 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학적 조성물
FR3101917B1 (fr) 2019-10-09 2022-07-15 Ifp Energies Now Système de refroidissement à radiateur unique
CN114159384B (zh) * 2021-02-07 2023-04-07 南京锐志生物医药有限公司 一种化学性质稳定的低刺激性酮咯酸氨丁三醇注射液
CN114432240A (zh) * 2022-03-04 2022-05-06 郑州市中心医院 一种稳定不刺激的酮咯酸氨丁三醇注射液及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1448184A (zh) * 2002-04-01 2003-10-15 永信药品工业股份有限公司 包含非－类固醇消炎药剂的可注射医药组合物及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089969A (en) 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US5214052A (en) 1987-07-28 1993-05-25 Mitsubishi Kasei Corporation Method for dissolving arginineamides and pharmaceutical compositions containing them
US6372755B2 (en) 1997-07-11 2002-04-16 Toray Industries, Inc. Stable medicinal compositions containing 4,5-epoxymorphinan derivatives
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
HRP20010780A2 (en) 1999-03-26 2002-12-31 Pozen Inc High potency dihydroergotamine compositions
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US6509027B2 (en) * 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
US20070049552A1 (en) 2003-04-14 2007-03-01 Babu Manoj M Fluoroquinolone formulations and methods of making and using the same
US20080317681A1 (en) * 2003-07-11 2008-12-25 Petros Gebreselassie Compositions containing a stain removing complex, and methods of making and using the same
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
CA2584184A1 (en) * 2004-10-15 2006-04-27 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
JP5189980B2 (ja) 2005-09-01 2013-04-24 バクスター・インターナショナル・インコーポレイテッド 可溶化剤として酸を含むアルガトロバン処方物
US20070142478A1 (en) 2005-12-21 2007-06-21 Erning Xia Combination antimicrobial composition and method of use
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
DOP2007000055A (es) * 2006-04-10 2007-10-31 Senosiain S A De C V Lab Composición farmaceutica que comprende un analgésico y vitaminas
KR20090040258A (ko) 2006-04-18 2009-04-23 이케이알 테라퓨틱스, 인코포레이티드 사전혼합된, 즉석용 약제 조성물
WO2007146795A2 (en) 2006-06-12 2007-12-21 Ironwood Pharmaceuticals, Inc. Pharmaceutical formulation for parenteral administration
CA2656087A1 (en) * 2006-06-29 2008-01-10 Schering Corporation Sugar-free storage-stable antihistaminic syrups
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US20080057023A1 (en) 2006-08-29 2008-03-06 Chynn Emil W Oxygenated ophthalmic composition
US7589106B2 (en) 2006-09-27 2009-09-15 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
KR100836624B1 (ko) 2006-12-08 2008-06-10 한국전자통신연구원 가변 고속 푸리에 변환 장치 및 그 방법
US20080312154A1 (en) * 2007-06-15 2008-12-18 Barbara Lee Peterlin Administration of adipocytokine and adiponectin for treating headache and methods of diagnosing headache by measuring adiponectin
CA2699172C (en) 2007-09-03 2016-05-17 Nanotherapeutics, Inc Compositions and methods for delivery of poorly soluble drugs
WO2009087658A2 (en) * 2007-11-07 2009-07-16 Sun Pharma Advanced Research Company Limited Composition suitable for parenteral administration
WO2009064928A1 (en) 2007-11-13 2009-05-22 Cadence Pharmaceuticals Reduced dose intravenous acetaminophen
US20090239836A1 (en) * 2008-03-24 2009-09-24 Mary Lee Ciolkowski Multifunctional Ophthalmic Compositions
US8956636B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
TWI397038B (zh) * 2008-11-05 2013-05-21 Au Optronics Corp 使用半源極驅動架構之顯示面板及其顯示資料供應方法
JP6188021B2 (ja) * 2010-07-19 2017-08-30 バイオジェン チェサピーク エルエルシー グリブリドおよび他の薬剤の静脈内投与方法
AU2011281035B2 (en) 2010-07-21 2014-10-02 Cumberland Pharmaceuticals, Inc. Acetycysteine compositions and methods of use thereof
WO2012054831A2 (en) 2010-10-21 2012-04-26 Rtu Pharmaceuticals, Llc Ready to use ketorolac formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1448184A (zh) * 2002-04-01 2003-10-15 永信药品工业股份有限公司 包含非－类固醇消炎药剂的可注射医药组合物及其制备方法

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103830171A (zh) * 2014-03-04 2014-06-04 鲁南制药集团股份有限公司 一种酮咯酸氨丁三醇注射液及其制备方法
CN103830171B (zh) * 2014-03-04 2015-11-18 鲁南制药集团股份有限公司 一种酮咯酸氨丁三醇注射液及其制备方法
CN110812325A (zh) * 2019-11-13 2020-02-21 鲁南制药集团股份有限公司 一种提高酮咯酸氨丁三醇注射液存储稳定性的方法
CN110812325B (zh) * 2019-11-13 2022-04-05 鲁南制药集团股份有限公司 一种提高酮咯酸氨丁三醇注射液存储稳定性的方法
WO2022241983A1 (zh) * 2020-05-19 2022-11-24 南京海融医药科技股份有限公司 一种左酮咯酸的药物组合物及其制备方法
CN115518035A (zh) * 2021-06-24 2022-12-27 上海博志研新药物技术有限公司 一种酮咯酸液体组合物、其制备方法及应用
CN115518035B (zh) * 2021-06-24 2024-02-27 上海云晟研新生物科技有限公司 一种酮咯酸液体组合物、其制备方法及应用
CN113384524A (zh) * 2021-07-05 2021-09-14 四川尚锐生物医药有限公司 一种稳定的酮咯酸氨丁三醇注射液的制备方法
CN114191384A (zh) * 2021-12-20 2022-03-18 成都倍特药业股份有限公司 一种即用型酮咯酸氨丁三醇和氢溴酸依他佐辛组合液体制剂

Also Published As

Publication number Publication date
KR102114568B1 (ko) 2020-05-22
EP2616064A4 (en) 2016-07-20
DK2616064T3 (da) 2019-11-11
US10278959B2 (en) 2019-05-07
PT2616064T (pt) 2019-11-06
WO2012054831A3 (en) 2012-06-07
CA2814805A1 (en) 2012-04-26
EP2616064A2 (en) 2013-07-24
HRP20191994T1 (hr) 2020-02-07
SI2616064T1 (sl) 2019-12-31
MX2013004393A (es) 2014-09-12
MX346879B (es) 2017-04-03
EP3632432B1 (en) 2022-09-14
US20220023260A1 (en) 2022-01-27
KR102307601B1 (ko) 2021-09-30
CY1122516T1 (el) 2021-01-27
LT2616064T (lt) 2019-11-25
ES2933198T3 (es) 2023-02-02
US11116750B2 (en) 2021-09-14
PL2616064T3 (pl) 2020-02-28
US9421191B2 (en) 2016-08-23
CN108703948A (zh) 2018-10-26
US20180280351A1 (en) 2018-10-04
WO2012054831A2 (en) 2012-04-26
HUE045889T2 (hu) 2020-01-28
KR20140012029A (ko) 2014-01-29
EP3632432A1 (en) 2020-04-08
KR20190085561A (ko) 2019-07-18
JP6013346B2 (ja) 2016-10-25
ES2753981T3 (es) 2020-04-15
SMT201900656T1 (it) 2020-01-14
US9962371B2 (en) 2018-05-08
US20190105301A1 (en) 2019-04-11
EP2616064B1 (en) 2019-08-07
US20170007575A1 (en) 2017-01-12
US20120101142A1 (en) 2012-04-26
KR20180119610A (ko) 2018-11-02
CA2814805C (en) 2021-11-02
RS59526B1 (sr) 2019-12-31
JP2013543843A (ja) 2013-12-09
KR20200078541A (ko) 2020-07-01
EP4190327A1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
CN103167800A (zh) 即用型酮咯酸注射液
CN110430879B (zh) 新组合物和方法
TWI844703B (zh) 穩定的ast-3424注射液製劑及製備方法
RU2362560C2 (ru) Фармацевтическая препаративная форма
US20180360822A1 (en) Intranasal naloxone compositions and methods of making and using same
CA2677281A1 (en) Transoral dosage forms comprising sufentanil and naloxone
CN110812325B (zh) 一种提高酮咯酸氨丁三醇注射液存储稳定性的方法
HK1262803A1 (en) Ready to use ketorolac formulations
HK40026993B (en) Ready to use ketorolac formulations
HK40026993A (en) Ready to use ketorolac formulations
AU2013263750B2 (en) Formulations for parenteral delivery of compounds and uses thereof
EP4048228A1 (en) Novel pediatric combination

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130619